Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.50 |
| ▸ | MMP2 | P08253 | 5/20 | 0.47 |
| ▸ | MMP9 | P14780 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.40 |
| ▸ | MMP12 | P39900 | 3/20 | 0.40 |
| ▸ | MMP14 | P50281 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118389 | 0.88 | ITGB3 (0.52) | ITGB3ITGA2BMMP2MMP9ITGAV | |
| SCHEMBL7144029 | 0.84 | ITGB3 (0.53) | ITGB3ITGA2BMMP2MMP9ITGAV | |
| SCHEMBL7144039 | 0.84 | ITGB3 (0.53) | ITGB3ITGA2BMMP2MMP9ITGAV | |
| SCHEMBL7033322 | 0.84 | ITGB3 (0.47) | ITGB3ITGA2BITGAVCA2 | |
| SCHEMBL7395698 | 0.83 | ITGB3 (0.47) | ITGB3ITGA2BMMP2MMP9ITGAV | |
| SCHEMBL6818957 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BITGAVNOD1 | |
| SCHEMBL31522342 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BITGAVNOD1 | |
| SCHEMBL7262653 | 0.81 | ITGB3 (0.52) | ITGB3ITGA2BITGAV | |
| SCHEMBL7262649 | 0.81 | ITGB3 (0.52) | ITGB3ITGA2BITGAV | |
| SCHEMBL4059094 | 0.80 | ITGB3 (0.51) | ITGB3ITGA2BMMP2MMP9ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | ITGB3 7/4885ITGA2B 106/4885MMP2 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.